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Abstract 
Background: In the present study the blood expression level of inflammatory response and autoimmunity associ-
ated long non-coding RNAs (lncRNAs) were compared in patients with different chronic respiratory diseases and 
investigated whether they could be used as biomarkers in these diseases.
Methods: In the discovery cohort, the gene expression level of 84 lncRNAs were measured in the blood of 24 adult 
patients including healthy controls and patients with asthma and COPD. In the replication cohort the expression of 6 
selected lncRNAs were measured in 163 subjects including healthy controls and adults with allergic rhinitis, asthma, 
COPD and children with asthma. It was evaluated whether these lncRNAs can be used as diagnostic biomarkers for 
any studied disease. With systems biology analysis the biological functions of the selected lncRNAs were predicted.
Results: In the discovery cohort, the mean expression of 27 lncRNAs showed nominally significant differences in at 
least one comparison. OIP5-AS1, HNRNPU, RP11-325K4.3, JPX, RP11-282O18.3, MZF1-AS1 were selected for measurement 
in the replication cohort. Three lncRNAs (HNRNPU, RP11-325K4.3, JPX) expressed significantly higher in healthy children 
than in adult controls. All the mean expression level of the 6 lncRNAs differed significantly between adult allergic 
rhinitis patients and controls. RP11-325K4.3, HNRNPU and OIP5-AS1 expressed higher in allergic asthma than in non-
allergic asthma. COPD and asthma differed in the expression of RP11-325K4.3 from each other. In examining of the 
lncRNAs as biomarkers the weighted accuracy (WA) values were especially high in the comparison of healthy controls 
and patients with allergic rhinitis. OIP5-AS1 and JPX achieved 0.98 and 0.9 WA values, respectively, and the combina-
tion of the selected lncRNAs also resulted in a high performance (WA = 0.98). Altogether, OIP5-AS1 had the highest 
discriminative power in case of three out of six comparisons.
Conclusion: Differences were detected in the expression of circulating lncRNAs in chronic respiratory diseases. Some 
of these differences might be utilized as biomarkers and also suggest a possible role of these lncRNAs in the patho-
mechanism of these diseases. The lncRNAs and the associated pathways are potential therapeutic targets in these 
diseases, but naturally additional studies are needed for the confirmation of these results.
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Background
Chronic respiratory diseases such as asthma, chronic 
obstructive pulmonary disease (COPD) and allergic rhi-
nitis cause an enormous burden on the societies and are 
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Over 1 billion people in the world suffer from chronic 
respiratory diseases [2, 3]. Patients with these diseases 
can have a profound impairment in their quality of life 
and work or school performance. During the last dec-
ades, the prevalence of chronic respiratory diseases has 
dramatically increased. While at the beginning of the 
twentieth century allergy was considered as a rare dis-
ease, today the most common form of allergic disease, 
allergic rhinitis, has a prevalence of about 25% in Europe, 
and within the next few decades more than half of the 
European population will have some type of allergy [4–
6]. Asthma, which is a complex chronic inflammatory 
disease accompanied by episodic airway obstruction 
and inflammation of the lower respiratory tract affects 
an estimated 358 million people worldwide and it is the 
most frequent chronic disease in children [7]. COPD is 
characterized by airway remodeling which is irrevers-
ible in most cases and undergoes progressive changes in 
contrast to the reversible narrowing of airways in asthma. 
COPD has an estimated annual death rate of over 4 mil-
lion people globally [8, 9].
While rhinitis is characterized by an inflammation of 
the upper airways, asthma and COPD are featured by an 
inflammation of the lower airways. Although these are 
separate disease entities, there is a considerable overlap 
between them [10]. Often allergic rhinitis can develop to 
asthma and most asthmatic children and a considerable 
portion of adults have both diseases [11–13]. Patients 
with COPD can also have asthma, which is called 
asthma-COPD overlap syndrome, or ACOS [14]. Recent 
epidemiological data show that COPD is also associated 
with chronic rhinitis which is a high-risk comorbidity 
for 30-day hospital re-admission of patients with both 
asthma and COPD [15–17].
In addition, all these diseases, especially asthma and 
COPD have several endotypes, i.e. different molecular 
pathomechanisms can lead to similar phenotypes. Pres-
ently, there are no or only very few biomarkers for accu-
rate classification of these diseases or to follow-up the 
responses to the therapies [9, 15].
Numerous studies have confirmed that 70–90% of the 
human genome is transcribed into RNA but only 1.2% 
has protein coding ability. Long non-coding RNAs (lncR-
NAs) are greater than 200 bp in length, building a major 
part of non-coding RNAs but in the meantime the least 
characterized [18]. Depending on the relative position of 
the sequence of long non-coding gene with respect to the 
protein-coding region, lncRNAs can be divided into dif-
ferent subgroups including natural antisense (AS), long 
intergenic (LINC), bidirectional-promoter, enhancer 
RNAs (eRNAs), promoter associated RNAs (PARs), ter-
minus associated RNAs (TARs) and intronic (INT) lncR-
NAs [19, 20]. They can participate in cell proliferation, 
differentiation, processes of programmed cell death and 
immune response by their capability of binding DNA, 
RNA and proteins and thereby influencing the transcrip-
tion process, chromatin remodeling, activity of mRNA 
and miRNA, localization and structure of proteins [21]. 
The altered expression of lncRNAs can play a role in 
various diseases including chronic respiratory diseases. 
LncRNAs show much greater cell-type specific expres-
sion pattern than mRNAs. It was also observed that dis-
ease-associated lncRNAs exhibit far greater differences 
in expression than disease-associated mRNAs and in 
this way lncRNAs are considered as potential biomark-
ers [22]. In addition, identifying lncRNAs associating 
with diseases or disease endotypes can contribute to the 
understanding of the pathomechanisms of these diseases.
In the present study, first we measured the gene expres-
sion level of 84 inflammatory response and autoimmun-
ity associated lncRNAs in the blood of patients with 
mild or moderate (Global Initiative for Asthma (GINA) 
1–3) and severe (GINA 4–5) asthma, COPD and control 
patients (discovery cohort). Then, based on these results 
and the scientific literature we selected 6 lncRNAs and 
compared their expression in an expanded population 
of patients with different chronic respiratory diseases 
including pediatric and adult asthma, mild and severe 
asthma, COPD, allergic rhinitis and in corresponding 
healthy controls. We also compared the expression of 
these lncRNAs in different subgroups of these diseases 
and investigated whether they could be used as biomark-
ers. Finally, we performed a systems biology analysis aim-




Our research consisted of two stages. In the discovery 
cohort, 24 adult patients were involved, out of which 6 
had mild or moderate asthma (GINA 1–3), 6 severe 
asthma (GINA 4–5), 6 COPD and 6 were healthy con-
trols. Participants with asthma were recruited from 
Asthma ambulance of National Korányi Institute of TB 
and Pulmonology and from the Department of Pulmo-
nology of Semmelweis University. Asthmatic subjects 
were diagnosed based on Global Initiative for Asthma 
(GINA) guidelines (www.ginas thma.org), as described 
previously [23]. COPD diagnosis was determined accord-
ing to the Global Initiative for Obstructive Lung Diseases 
(https ://goldc opd.org) designation. Control subjects were 
healthy donors. Some characteristics of these subjects are 
summarized in Table 1.
The replication cohort consisted of 163 subjects. This 
cohort included 11 asthmatic children from the Allergol-
ogy Department of Heim Pál Children’s Hospital, 95 adult 
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patients with asthma, 9 with COPD from the Asthma 
ambulance of National Korányi Institute of TB and Pul-
monology, and from the Department of Pulmonology of 
Semmelweis University. Out of the asthmatic patients 31 
had severe asthma (GINA 4–5) and 64 mild or moderate 
asthma (GINA 1–3). Adult patients with allergic rhini-
tis were selected from patients of five Hungarian aller-
gic outpatient centers with documented ragweed allergy 
with clinical history for at least 2 years with peak symp-
toms in August–September. Detailed description of this 
project, named DesensIT can be found elsewhere [24]. 
These patients had moderate-severe seasonal allergic rhi-
nitis based on Allergic Rhinitis and its Impact on Asthma 
(ARIA) criteria and their respiratory symptoms remained 
troublesome despite avoidance or adequate pharmaco-
logic therapy, interfering with usual daily activities or 
with sleep during the pollen season. The blood was col-
lected outside of the pollen season. The control group 
consisted of 23 individuals with no history of asthma or 
allergy. Control children (n = 16) were patients from the 
Department of Ear, Nose and Throat Medicine of Heim 
Pál Children’s Hospital. Control adults (n = 7) were 
healthy donors. More information about the replication 
cohort can be found in Table 2.
Subjects were all Caucasian with about 5% Gypsy ori-
gin based on Hungarian statistical databases. Written 
informed consent was provided by all participants or 
parent/guardian at the time of recruitment. The study 
was conducted according to the designations deter-
mined in the Declaration of Helsinki and approved by 
the Hungarian Scientific and Research Ethics Com-
mittee of the Medical Research Council (ETT TUKEB; 
Case No.: 3526–0/2010-1018EKU; 14,666–1/2012/EKU; 
IF-980–9/2016).
Whole blood collection
Whole blood samples (2.5  ml) were collected in PAX-
gene Blood RNA Tube (PreAnalitiX, Qiagen, Venlo, The 
Netherlands) to avoid rapid RNA degradation and to sta-
bilize the intracellular RNA. Thereafter, PAXgene tubes 
were carefully inverted 8 to 10 times and stored for 2 h to 
3 days at room temperature before long-term storage in 
freezer (− 20 °C).
Total RNA isolation and reverse transcription
Prior to RNA extraction, after tubes were removed 
from − 20 °C, they were allowed to thaw and incubated at 
room temperature for 2 h. RNA purification was carried 
out according to the protocol in the manual of PAXgene 
Blood RNA Kit. RNA concentrations were measured 
using a NanoDrop ND-1000 spectrophotometer (Nan-
oDrop Technologies, Wilmington, DE, USA) and the 
purity of RNA was determined based on the  A260/A280 
ratio, 1.8–2.2 was accepted as pure.
In the discovery cohort, before the reverse tran-
scription, due to the low amount of isolated RNA, 
Table 1 Characteristics of the study subjects in the discovery cohort
Control n = 6 Mild asthma n = 6 Severe asthma n = 6 CODP n = 6
Age (Mean ± SD) 36.7 ± 12 46 ± 19 53.7 ± 19 58.5 ± 12
Gender (Male/Female) 3/3 3/3 0/6 3/3
Eosinophil cell count [%] (Mean ± SD) – 4.4 ± 5 6.9 ± 6 1.8 ± 3
Neutrophil cell count [%] (Mean ± SD) – 67 ± 29 61.4 ± 6 74 ± 11
FEV1 [%] (Mean ± SD) – 88.8 ± 21 72.8 ± 26 59 ± 26
Allergic rhinitis (yes/no) 0/6 3/3 5/1 1/5
Table 2 Characteristics of the study subjects in the replication cohort
Childhood control Childhood asthma Adult control Adult asthma COPD Allergic rhinitis
n (number of samples) 16 11 7 95 9 25
Age (Mean ± SD) 9.6 ± 2 13.5 ± 4 36.4 ± 11 48.3 ± 13 61.6 ± 12 43.5 ± 11
Gender (Male/Female) 8/8 9/2 3/4 39/56 4/5 10/15
Mild or moderate/Severe asthma – 11/0 – 64/31 – –
Eosinophil cell count [%] (Mean ± SD) – 3.7 ± 3 – 5.2 ± 4 3.8 ± 5 –
Neutrophil cell count [%] (Mean ± SD) – 50.4 ± 25 – 60.7 ± 31 67.2 ± 33 –
FEV1 [%] (Mean ± SD) – 110.4 ± 16 – 85.8 ± 21 64.3 ± 3 106.4 ± 13
Allergic rhinitis (yes/no) 0/16 10/1 0/7 74/21 3/6 25/0
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amplification was carried out with  RT2 PreAMP cDNA 
Sythesis Kit (Qiagen, Hilden, Germany). In the rep-
lication study, because of the TaqMan Non-Coding 
experimental design, High Capacity RNA-to-cDNA Kit 
(Thermo Fisher, Waltham, MA, USA) was used.
LncRNA PCR array and assay
The pre-amplified cDNA was measured with a prefabri-
cated Human  RT2 lncRNA PCR Array (LASH-004Z, Qia-
gen, Hilden, Germany). This panel consists of 84 verified, 
pre-validated primer pairs specific for the target genes 
associated with inflammatory response and autoimmun-
ity. The array also contains 5 primer pairs for housekeep-
ing genes (SNORA73A, RN7SK, RPLP0, B2M, ACTB), 1 
for the detection of human genomic DNA contamina-
tion, 3 for reverse transcription control and 3 for positive 
PCR control.  RT2 SYBR Green ROX qPCR Master Mix 
(Qiagen, Hilden, Germany) was used for real-time PCR 
reaction on Applied Biosystems 7900HT instrument with 
96-Well Block Module.
In the replication cohort, expression level of 6 lncRNAs 
and 2 reference genes were detected with TaqMan Non-
coding RNA Assays (JPX: Hs0139517_g1; AC016629.8: 
Hs03678951_m1; HNRNPU: Hs00402532; OIP5-AS1: 
Hs01587687_g1; RP11-282O18.3: Hs00416786_m1; 
RP11-325K4.3: Hs01594146_s1) and Gene Expression 
Assays (B2M: Hs99999907_m1; RPLP0: Hs00420895_gH) 
with Gene Expression Master Mix (all from Applied Bio-
systems, Waltham, MA, USA). The measurements were 
performed in duplicate on 384-well plate (ABI 7900HT) 
in 10 μl of total PCR Reaction Mix volume.
Statistical analysis
Analysis of differential expression
All statistical analyses were performed using R statisti-
cal software (R Foundation for Statistical Computing, 
Vienna, Austria; version 3.6.3). Normalized RNA expres-
sion levels were calculated using the formula  2−ΔCt, 
where Ct = Ct(target RNA) − 
−
Ct(normalizing factor); 
Ct(.) is the threshold cycle value of a given gene and 
−
Ct (.) 
is the arithmetic mean of the threshold cycle values of 
certain genes. For the discovery cohort, all five house-
keeping genes contained by the prefabricated Human 
 RT2 lncRNA PCR Array were used for normalization. 
For the validation, B2M and RPLP0 were utilized as ref-
erence genes because of their relatively stable level of 
expression. Statistical differential expression of lncRNAs 
was determined by the Limma package [25]. For that, a 
linear model was fitted for each lncRNA based on the 
subgroup of the patients. Then, moderated t-statistics 
and log-odds of differential expression were calculated 
by empirical Bayes moderation of the standard errors 
towards a common value. The resulting nominal p-values 
were corrected for multiple testing using the Benjamini–
Hochberg procedure for each comparison. LncRNAs 
were considered to be differentially expressed when the 
adjusted p-value was below 0.05. Principal component 
analysis of lncRNA expression data was performed with 
the prcomp function of R.
Analysis of the lncRNAs as diagnostic biomarkers
To analyze the potential usefulness of the six lncRNAs 
(chosen for the replication cohort) as diagnostic bio-
markers in the studied chronic respiratory diseases, we 
created Naïve Bayesian classifiers using the e1071 pack-
age in R [26]. The models were based on the normal-
ized expression levels of different lncRNA combinations, 
namely using (1) each lncRNA alone, (2) all six lncRNAs, 
and (3) only those that showed statistically significant 
expression differences in case of a particular comparison.
As the number of patients varied highly in the different 
subgroups, we assessed the performance of the classifica-
tion models by computing their weighted accuracy (a.k.a. 
balanced accuracy) defined by the following formula:
where one of the classes (i.e. patient subgroups) is con-
sidered “positive”, and the other “negative”, and TP is 
the number of true positives, TN is the number of true 
negatives, FN is the number of false negatives, and FP 
is the number of false positives in the confusion matrix. 
This formulation assesses the accuracy for each class and 
weighs them equally independently from the number of 
samples belonging to the class.
We calculated the confusion matrix for each model 
by a leave-one-out cross-validation scheme as the fol-
lowing: For a given comparison, we left out one sample 
and trained the model using all other samples. Next, we 
predicted the class of the left-out sample using a default 
cut-off of probability 0.5, and compared the predicted 
class label with the true one of that sample. Each step 
of this procedure yielded one element of the confu-
sion matrix based on which we computed the weighted 
accuracy as described above.
Prediction of the putative functions of lncRNAs
We performed a systems biology analysis to identify the 
putative functional pathways and Gene Ontology terms 
associated with each of the six lncRNAs (chosen for the 
replication cohort). The overview of this analysis can be 
seen in Additional file 1 and the detailed description of 
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Results
Results of the discovery study
In the discovery group, using a prefabricated human 
inflammatory response and autoimmunity array, the 
expression levels of 84 lncRNAs were measured in the 
blood of 6 patients with mild or moderate asthma (GINA 
1–3), 6 with severe asthma (GINA 4–5), 6 with COPD, 
and in 6 healthy controls (Table 1). Based on the quality 
controls, the results of a COPD patient were excluded 
from the evaluation. The heatmap of the relative expres-
sion of the lncRNAs (ΔCt values relative to the reference 
lncRNA genes) in each sample is depicted in Additional 
file  2. No lncRNA showed statistically significant differ-
ential expression between the two genders in any disease 
group (data not shown). Among the lncRNAs on the 
panel, there were 2 lncRNAs which showed inherently 
different expressions in the two genders: XIST, which 
is involved in the inactivation of the X chromosome in 
women, and NAV2-AS5, which is mainly expressed in the 
testis. These two genes were excluded from the selection. 
Interestingly, there was no such gender dependent differ-
ence in the expression of JPX, although according to the 
scientific literature this lncRNA is transcribed within the 
X-inactivation center and activates the expression of the 
XIST gene [27].
The expression level of these lncRNAs were compared 
between different groups of patients. In these compari-
sons the allergic status of the patients was also consid-
ered. According to the phenotypes of the patients, 13 
comparisons were made. The compared groups and the 
heatmap based on the  log2FC and sex-adjusted P-values 
can be seen in Additional file 3, Additional file 4 and in 
Additional file  5. Altogether the mean expression of 
27 lncRNAs showed nominally significant differences 
(P < 0.05) in at least one comparison (Fig.  1). Most dif-
ferences were found between mild and severe asthma 
groups. In this comparison 22 out of 84 lncRNAs showed 
nominally significant differences. Nine lncRNAs showed 
expression differences between COPD and severe 
asthma, 3 between asthma and COPD, 3 between asthma 
and control, 9 between severe asthma and control, 1 
between COPD and control, 2 between mild asthma and 
control groups.
In previous studies two lncRNAs (OIP5-AS1, 
HNRNPU) have been indirectly associated with eosino-
phil asthma [28, 29]. In our measurements, HNRNPU 
showed increased expression in severe asthma compared 
with mild asthma, while OIP5-AS1 showed increased 
expression in COPD compared to asthma (Fig. 1; Addi-
tional file  5). Based on these differences, and data from 
the scientific literature and databases, 6 lncRNAs were 
selected for the replication cohort (OIP5-AS1, HNRNPU, 
RP11-325K4.3, JPX, RP11-282O18.3, AC016629.8 later 
renamed to MZF1-AS1). It must be added that dur-
ing our study the transcript variations of the HNRNPU 
which are not translated to a protein and were considered 
as lncRNAs were withdrawn from the database, in this 
way, we probably investigated the expression of a protein-
coding gene. But, for the sake of simplicity, in this paper, 
we refer to this gene also as an lncRNA.
Results in the replication cohort
In the replication cohort 163 patients were involved in 6 
different groups (Table 2). In our comparisons the aller-
gic status of the asthmatic patients was also considered 
and these patients were also stratified according to the 
severity (GINA 1–3 vs. GINA 4–5), in this way, 10 differ-




















































































































































Fig. 1 Statistical significance and expression changes of lncRNAs 
(rows) which showed at least one nominally significant expression 
difference (P < 0.05) in a given comparison (columns) in the discovery 
cohort
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can be seen in Additional file 6 and the heatmap based on 
the −  log10P-values of the expression differences between 
the groups in Additional file 7. The significant differences 
can be seen in Table 3.
Interestingly, three lncRNAs (HNRNPU, RP11-
325K4.3, JPX) expressed significantly higher in pediat-
ric controls than in adult controls (Additional file  8). 
Because of this, the results when the two age groups were 
merged (e.g. in case of asthma) were excluded from the 
evaluations.
The most and largest differences were found between 
adult allergic rhinitis and control patients (Fig.  2). In 
these cases, the mean expression levels of all 6 lncRNAs 
differed significantly between the two groups. Principal 
component analysis indicated that the lncRNAs could be 
separated into two distinct, uncorrelated groups, namely 
OIP5-AS1, HNRNPU, RP11-325K4.3 and JPX, RP11-
282O18.3, MZF1-AS1, in which the lncRNAs correlated 
with each other (c.f. the orthogonal loading vectors of 
lncRNAs in the right panel of Fig. 2). However, in respect 
of allergy, OIP5-AS1 seemed to be the most important, 
since its mean expression level was significantly higher in 
all cases, where allergy was involved. It was also higher 
in allergic patients without asthma than in allergic asth-
matic patients. A summary of all results can be seen in 
Figs. 3, 4. It can be seen in the figures that in respect of 
these lncRNAs, allergic rhinitis differed most significantly 
from any other phenotypes. In allergic rhinitis the mean 
expressions of five lncRNAs (RP11-325K4.3, OIP5-AS1, 
JPX, HNRNPU, MZF1-AS1) were significantly higher 
than in COPD, three (OIP5-AS1, HNRNPU, JPX) than in 
asthma, five (OIP5-AS1, HNRNPU, RP11-325K4.3, RP11-
282O18.3, JPX) than in non-allergic asthma and one 
(OIP5-AS1) than in allergic asthma. Adult allergic and 
non-allergic asthma differed in the expression of three 
lncRNAs from each other, RP11-325K4.3, HNRNPU and 
OIP5-AS1 expressed higher in allergic asthma. COPD 
and asthma differed in the expression of one lncRNA 
Table 3 Log2FC and adjusted P-values in the comparison of different groups in the replication cohort in respect of mean 
blood expression level of lncRNAs. Only those results are given where the adjusted P < 0.05
All the results can be seen in Additional file 6
Comparison lncRNA Log2FC Adjusted P value





Adult allergic asthma vs. Adult non-allergic asthma RP11-325K4.3 0.71 0.0007
HNRNPU 0.67 0.0007
OIP5-AS1 0.37 0.0374
Adult allergy vs. Adult allergic asthma OIP5-AS1 0.38 0.0423
Adult asthma vs. Adult COPD RP11-325K4.3 0.82 0.0092
Childhood control vs. Adult control HNRNPU 1.01 0.0079
RP11-325K4.3 0.96 0.0092
JPX 0.85 0.0162
Adult allergic rhinitis vs. Adult asthma OIP5-AS1 0.56 0.0005
HNRNPU 0.43 0.0211
JPX 0.41 0.0226
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from each other. RP11-325K4.3 expressed significantly 
higher in the blood of asthmatics than in patients with 
COPD. The comparisons where significant differences 
(adjusted P < 0.05) were found can be seen in Additional 
file 9–14.
In contrast to the discovery cohort, in this expanded 
population none of the lncRNAs showed association 
with asthma severity. No differences were found between 
pediatric asthma and controls. In the replication cohort 
similarly to the discovery cohort, JPX did not show a gen-
der specific expression.
Next, we also analyzed whether the expression of these 
lncRNAs differ in different subgroups of asthma. No dif-
ferences were found when asthmatic patients were strati-
fied according to their lung functions (FEV1 < 80% vs. 
FEV1 > 80%), inhaled corticosteroid usage (regular vs. 
non-regular), severity, and controllability (controlled vs. 
non-controlled). We also tested whether the expression 
levels of these lncRNAs correlated with the blood eosino-
phil or neutrophil levels but found no correlation (data 
not shown).
LncRNAs as biomarkers
Next, we investigated, whether these lncRNAs can be 
used as diagnostic biomarkers for any studied chronic 
respiratory disease. The results can be seen in Fig. 5.
Classifying adult allergic rhinitis patients and adult 
controls, three models achieved a very high perfor-
mance (WA = 0.98 in case of (1) using OIP5-AS1 alone, 
(2) using all six lncRNAs, which is the same model as 
(3) using all significant lncRNAs with respect to the 
given comparison). Clearly, these models utilized the 
high discriminative power of OIP5-AS1. Comparing 
adult COPD and adult patients with allergic rhinitis, 
using all five significant lncRNAs also resulted in a high 
performance (WA = 0.85).
In certain cases, combining all six lncRNAs resulted 
in significantly higher performance than any individual 
lncRNAs. Comparing adult allergic rhinitis and asth-
matic patients, the best model using individual lncR-
NAs resulted in a WA of 0.53, however, combining all 
six lncRNAs resulted in a WA of 0.7. Similarly, compar-
ing adult COPD and adult asthmatic patients, the best 
individual model had a WA of 0.53, and the full model 
had 0.61, respectively.
In other cases, using the combination of those lncR-
NAs that showed statistically significant expression dif-
ferences resulted in a slightly higher performance than 
the full model. Namely, in case of the aforementioned 
comparison of adult COPD and adult allergic rhinitis 
patients, and in case of comparing adult allergic asth-
matic and non-allergic asthmatic patients (WA = 0.65 
and 0.68 in case of the full model and the reduced 
model, respectively).
The OIP5-AS1 lncRNA had the highest discriminative 
power in case of three out of the six comparisons. More-
over, comparing adult patients with allergic and adult 





































































Adult allergy Adult control
Fig. 2 Left: Comparison of the blood expression of the 6 selected lncRNAs between adult patients with allergic rhinitis and controls. The adjusted 
P-values are given for each comparison. Right: Principal component analysis bi-plot showing the scores of the samples (colored circles) and the 
loadings of the variables (i.e. the six selected lncRNA as grey arrows) along the first two principal components
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individual OIP5-AS1 had the highest performance of all 
models (WA = 0.74, which is 5 percent point higher than 
the second-best model).
Predicted function of the studied lncRNAs
Finally, we aimed to predict the biological functions asso-
ciated with the six lncRNAs that were selected for the 
replication study in order to gain insight into their under-
lying biological processes (see details in the Additional 
file 15).
The results can be seen in Fig.  6. We found no over-
lap between the statistically significant (FDR < 0.1) pre-
dicted functions of the six lncRNAs. JPX is predicted 
to influence several immune-related processes, such as 
immune effector process (FDR = 0.084), cell activation 
involved in immune response (FDR = 0.084), the neutro-
phil degranulation pathway (FDR = 0.035) and the innate 
immune system pathway (FDR = 0.035). HNRNPU is pre-
dicted to have an effect on several FGFR2 related path-
ways, namely the signaling by FGFR2 in disease pathway 
(FDR = 0.094), the signaling by FGFR2 IIIA TM pathway 
(FDR = 0.094) and the FGFR2 mutant receptor activa-
tion pathway (FDR = 0.094). MZF1-AS1 is predicted to 
affect several pathways that regulate cell cycle, cell dif-
ferentiation/development, proliferation and metabolism, 
e.g. the PI3K−Akt signaling pathway (FDR = 0.071), the 
focal adhesion −PI3K−Akt−mTOR−signaling pathway 
(FDR = 0.071) and the nuclear receptors meta —pathway 
(FDR = 0.014). RP11-325K4.3 is predicted to affect devel-
opmental processes, such as keratinization (FDR = 0.01). 
RP11-282O18.3 is predicted to influence amino acid 
metabolism (FDR = 0.063). In case of OIP5-AS1, the 
method did not identify any biological processes or path-
ways. However, it was predicted that genes that are anno-
tated with the transport vesicle and the exocytic vesicle 
cellular components were significantly enriched among 
its predicted targets (FDR = 0.04).
Discussion
In the present study we measured the expression of 
inflammatory response and autoimmunity associated 
lncRNAs in the blood of patients with different chronic 
respiratory diseases. We detected several differences 
and identified an lncRNA, OIP5-AS1, with a very high 
potency to discriminate patients with severe pollen 
allergy from non-allergic patients.
In the stage I or discovery study, a smaller number 
of patients with chronic respiratory diseases and con-
trols were screened with 84 lncRNAs. According to the 
results of the measurements and data from the scien-
tific literature, 6 lncRNAs were selected for testing on an 
expanded population. During our study, several studies 
have been published where the expression of lncRNAs 
were tested in different chronic respiratory diseases, 
mainly in asthma, and several differences were found. 
Some of them were also measured in our stage I study. 
In our discovery cohort we did not find differences in 
any comparison in the expression of TUG1, MALAT1, 
NEAT1 and MEG3, all of them were found to be associ-
ated with asthma in different studies [30–33]. Although 
we measured the expression of these lncRNAs in the 
blood of only a small number of subjects (6 with mild-
moderate, 6 with severe asthma and 6 controls), the lack 
of differences suggests that they are possibly not suitable 
for general asthma blood biomarkers. Naturally, they still 















































































































































































Fig. 3 Statistical significance and expression changes of lncRNAs 
(rows) which showed at least one statistically significant blood 
expression difference (adjusted P < 0.05) in a given comparison 
(columns) in the replication cohort
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tissue-specific manner or might be biomarkers for some 
endotypes or treatment responses. Small, but moderately 
significant differences were found in the expression of 
GAS5 and its antisense GAS5-AS1 in certain compari-
sons. These lncRNAs were not selected for the replica-
tion study, because the differences were not exceedingly 
significant (unadjusted P-values were just below the sig-
nificance level) and at the time of the selection no data 
about their roles were available in the scientific literature. 
But, the fact that in a later study the expression of GAS5 
was found to be higher in asthmatics, and knock-down 
of GAS5 significantly decreased airway hyperresponsive-
ness in asthmatic rats, together with our results indicate 
their possible roles in asthma [34].
The expression of the selected lncRNAs were meas-
ured in an expanded population. The largest differences 
were found between controls and patients with allergic 
rhinitis. The expression of all selected lncRNAs were sig-
nificantly higher in patients with allergic rhinitis. Among 
these, OIP5-AS1, HNRNPU and JPX are the best studied. 
Using a combination of three biological networks we also 
carried out a bioinformatic analysis to predict the bio-
logical function and the associated GO terms of these six 
lncRNAs.
OIP5-AS1 is a conserved gene acting as a sponge for 
multiple cellular RNAs and microRNAs, regulating mito-
sis, maintaining cell proliferation, and functioning as an 
oncogene in several cancers [35–38]. Interestingly, OIP5-
AS1 by binding to miR-200b, also regulates indirectly the 
expression of ACE2, the receptor for COVID-19, but its 
implication in the infection has not yet been studied [39]. 
It was also found to be co-expressed with genes associ-
ated with eosinophilic asthma [28, 29], but its role in 
allergic rhinitis was not yet investigated. Our bioinfor-
matic analysis showed that genes that were annotated 
with the transport vesicle and the exocytic vesicle cellular 
components were significantly enriched among the pre-
dicted targets of OIP5-AS1. In our study its mean expres-
sion level was significantly higher in all diseases, where 
allergy was involved, e.g. in allergic rhinitis vs. COPD or 
in allergic asthma vs. non-allergic asthma, but its highest 
level was measured in allergic rhinitis.
The situation with the HNRNPU gene is more com-
plicated. It has several aliases in the databases, and 
earlier it was determined that there are several tran-
scripts from its genome locus, including those that are 
not translated into a protein (HNRNPU-AS1, which 
were considered as lncRNAs and were on the pre-
made array used in our measurement), but recently 
these have been withdrawn from the databases [40]. 
In this way the investigated HNRNPU gene is prob-
ably a protein-coding gene. The function of the pro-
tein, however, is similar to several lncRNAs, namely 


















Fig. 4 Summary of the different comparisons where at least one of the 6 selected lncRNAs showed statistically significant difference. All arrows 
indicate significant expression differences. The arrows with different colors denote the lncRNAs, depicted in the right side of the figure, the 
directions of the arrow indicate the expression levels. The arrows always point to the smaller mean blood expression levels. In the control group C 
stands for child, A for adult
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ribonucleoprotein complexes in the nucleus with het-
erogeneous nuclear RNA and plays important role in 
three-dimensional genome organization. As we have 
measured gene expression (i.e. RNA), we think that the 
characteristics of an RNA whether it is translated into 
a protein or not, cannot influence its possible use as a 
biomarker, thus we assume that involving this protein-
coding gene in the evaluations did not cause bias in our 
results. HNRNPU was found to be implicated in several 
processes, including regulation of the innate immu-
nity, proliferation and several diseases like cancers and 
eosinophilic asthma [28, 29, 41–45]. Our bioinformatic 
analysis showed that HNRNPU was associated with 
several FGFR2 related pathways.
The best-known role of JPX is that it serves as a molec-
ular switch in the X chromosome inactivation in females, 
but studies also show that it is implicated in different 
cancers and can act as an oncogene in certain cases while 
as a tumor suppressor in others [27, 46]. JPX is predicted 
to influence several immune-related processes, such 
as immune effector process, cell activation involved in 
immune response, the neutrophil degranulation path-
way and the innate immune system pathway. The lncRNA 
MZF1‐AS1 was identified as a transcriptional regulator 
of proline synthesis and neuroblastoma progression and 
was associated with several pathways that regulate cell 
cycle, cell differentiation/development, proliferation and 
metabolism [47].
In respect of RP11-325K4.3 and RP11-282O18.3 until 
now no publications have been found. Our bioinformatic 
analysis predicted that RP11-325K4.3 was associated 
with developmental processes, while RP11-282O18.3 
with amino acid metabolism.
0.53 0.50 0.49 0.50 0.49 0.50
0.61
0.49























Adult allergy vs. Adult asthma Adult allergic asthma vs. Adult non−allergic asthma Adult allergy vs. Adult non−allergic asthma

























































































































































Fig. 5 Weighted accuracy of the Naïve Bayesian classification models in different comparisons. Six comparisons were investigated, whether the 
6 lncRNAs, alone or in combination were suitable for biomarkers. Naïve Bayesian classifiers based on the normalized expression levels of different 
lncRNA combinations were created, namely (1) using each lncRNA alone, (2) all six lncRNAs (i.e. the full model), and (3) only those that showed 
statistically significant expression differences in case of the given comparison (i.e. the reduced model). The performances of the classification 
models were assessed by computing their weighted accuracy utilizing a leave-one-out cross-validation scheme. Color codes: blue: lncRNAs 
showing no expression differences between the two groups; red: lncRNAs showing significant differences between the two groups; green: all 
lncRNAs
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Some of the studied genes (HNRNPU, RP11-325K4.3, 
JPX) showed significantly higher expression in children 
than in adults. As HNRNPU and JPX are both implicated 
in cell proliferation, their increased blood levels in chil-
dren suggest that they might have roles in their develop-
ment. The function of RP11-325K4.3 has not yet been 
clarified, but its increased level in children also confirms 
its possible role in developmental processes found in our 
bioinformatic analysis. It is also noteworthy, that this 
was the only lncRNA that showed significant difference 
between adult asthma and COPD. The expression of the 
investigated genes, however, did not differ between asth-
matic children and controls.
According to a study where ageing-associated changes 
in the expression of lncRNAs in adult human tissues were 
investigated (between 20 and 79 years of age) no lncRNA 
was identified in the blood that showed age-dependent 
expression [48]. It suggests that after reaching adulthood 
the expression of lncRNAs do not change any more in 
the blood, and in this way blood expressed lncRNAs in 
adulthood might be used as age-independent biomark-
ers. Naturally, this must be tested in larger and diverse 
populations.
Perhaps, the most interesting finding of this study is 
the large significant differences between healthy con-
trols and allergic rhinitis patients in the expression of the 
selected circulating lncRNAs. Until now no paper has 
been published about the human blood levels of lncRNAs 
in allergic rhinitis. We also tested whether these lncR-
NAs are suitable as biomarkers. Those comparisons were 
analyzed where at least one significant difference was 
found. For the evaluations the Naïve Bayesian classifiers 
were used. The selected lncRNAs were tested individu-














































































































SIGNALING BY FGFR2 IIIA TM
SIGNALING BY FGFR2 IN DISEASE
Amino Acid metabolism − WP3925
Cytoplasmic Ribosomal Proteins − WP477
Focal Adhesion−PI3K−Akt−mTOR−signaling pathway − WP3932
Metapathway biotransformation Phase I and II − WP702
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Fig. 6 Results of a systems biology analysis of the selected lncRNAs to identify the associated functional biological mechanisms. A network 
propagation algorithm was initiated from each of the six lncRNAs in a combined heterogeneous lncRNA-gene network to quantitatively prioritize 
the genes that are expected to be regulated by the given lncRNA. Then, based on the prioritized target genes, gene set enrichment analysis (GSEA) 
was performed to identify the functionally relevant pathways and Gene Ontology terms. For further details of the method, see the Additional file 15. 
The color of the dots indicates the statistical significance of the enrichment and the size of the dots indicates the normalized enrichment score for 
the enriched term in case of the predicted targets of a given lncRNA. FDR: false discovery rate, NES: normalized enrichment score
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levels of the lncRNAs showed highly significant differ-
ences between two groups (e.g. RP11 − 325K4.3 in COPD 
vs. asthma (adjusted P = 0.0092) and COPD vs. allergic 
rhinitis (adjusted P = 0.0002)), still its discriminative 
power, due to its high variance, was low (weighted accu-
racy (WA) = 0.49 and 0.52, respectively). In these cases, 
the given lncRNA is not suitable for being a circulating 
blood biomarker, but these differences suggest that it 
might have a role in the pathomechanism of one of these 
diseases or their endotypes. In some cases, however, the 
lncRNAs alone or in combinations achieved very high 
performances. The WA values were especially high in the 
comparison of healthy adult controls and adult patients 
with allergic rhinitis. OIP5-AS1 and JPX achieved 0.98 
and 0.9 WA values, respectively, and the combination of 
the selected lncRNAs also resulted in a high performance 
(WA = 0.98). The WA values were also high in the com-
parison of COPD and allergic rhinitis (WA = 0.85 using 
the five significant lncRNAs and 0.81 when using OIP5-
AS1 alone), although 30% of the COPD patients also 
had allergic rhinitis. The WA value was not very high 
in comparison of allergic vs. non-allergic asthma (0.68 
when lncRNAs with statistically significant expression 
differences were used) but because there is still no solid 
biomarker in the differential diagnosis of these two endo-
types, an additional biomarker might be worth testing 
[49].
Although the diagnosis of allergic rhinitis is relatively 
straightforward (e.g. symptoms, skin prick test, aller-
gen-specific IgE), there is still no objective biomarker in 
allergen specific immunotherapy (AIT) which is able to 
track how patients respond to the therapy. Presently, the 
evaluation of clinical improvement is based on changes 
in subjective clinical and immunological parameters. Dif-
ferent algorithms have been developed for calculating 
adjusted symptom and medication scores, but none of 
them is universally accepted [24]. Naturally, it cannot be 
definitely stated that OIP5-AS1, JPX or the combination 
of these 6 lncRNAs will be useful biomarkers in AIT, but 
they are worth testing. In 5 of the 6 cases their expres-
sion levels were more than twice those of in the con-
trols. Especially the OIP5-AS1 is quite promising, whose 
expression level showed relative small variances in both 
patients and controls, and its discrimination potential, 
even alone, was very high. It must be noted, however, that 
the samples were collected in May and June, while the 
ragweed peak season in Hungary is between August and 
October. Presently, it is not yet known what the blood 
levels of these lncRNAs are when the symptoms are seri-
ous, and how they change during AIT. But, their signifi-
cantly higher expressions indicate that they are possibly 
involved in the pathomechanism of allergic rhinitis and 
they are potential novel drug targets. E.g. it is well-known 
that the majority of symptoms in allergy are caused by 
exocytosis of pre-formed inflammatory mediators-con-
taining granules from mast and basophil cells elicited 
by FcεRI upon binding of the allergen to receptor bound 
allergen-specific IgE. According to our bioinformatic 
analysis OIP5-AS1 is associated with transport vesicle 
and exocytic vesicle cellular components. Its higher level 
in allergic patients might indicate a connection of OIP5-
AS1 with this process suggesting a potential drug or ther-
apeutic target.
Some limitations of the study must also be mentioned. 
The estimated number of lncRNAs in the human genome 
is more than 50,000 [50], although their annotations are 
far from complete (see the case of HNRNPU-AS1). In the 
present study, only 84 selected lncRNAs were involved. 
Methods with higher capacity (e.g. RNA-seq) additional 
lncRNAs with larger potentials might be identified. In 
some groups, the number of study subjects were low. 
Moreover, in these diseases a lot of additional endotypes 
exist that were not tested in the present study. Additional, 
larger studies with more patients with verified, diverse 
endotypes are needed to utilize the biomarker potential 
of these lncRNAs and to get better understanding of their 
roles in these diseases.
Conclusion
Differences were detected in the expression of circulating 
lncRNAs in chronic respiratory diseases. Some of these 
differences might be utilized as biomarkers and also sug-
gest a possible role of these lncRNAs in the pathomecha-
nism of these diseases. With a systems biology analysis, 
novel functions of some of the lncRNAs were predicted. 
The lncRNAs and the associated pathways are potential 
therapeutic targets in these diseases, but naturally addi-
tional studies are needed for the confirmation of these 
results.
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Additional file 1: Overview of the systems biology analysis to identify the 
functional pathways and Gene Ontology terms of the 6 selected lncRNAs. 
A. Construction of a meta-network consisting of two types of meta-nodes, 
namely lncRNAs and genes; and four meta-edges, namely (1) the tissue-
specific transcriptional similarity of lncRNAs, (2) the tissue-specific tran-
scriptional similarity between lncRNAs and genes, (3) the experimentally 
validated lncRNA-target gene pairs connecting lncRNAs and genes, and 
(4) protein-protein interaction of genes. B. The heterogeneous lncRNA-
gene network induced by the meta-network. Diamond-shaped nodes 
represent lncRNAs, and circular nodes represent genes. Edges represent 
functional connection between the corresponding nodes consistent with 
the meta-edges. C. A random walk with restart network propagation algo-
rithm is initiated from each of the six lncRNAs to quantitatively prioritize 
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particular lncRNA. The color of the nodes represent the amount of propa-
gated information in that node (i.e. steady state probability of the random 
walker visiting that particular node). D. Schematic representation of gene 
set enrichment analysis on the propagated gene scores.
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of the blood expression of the 6 selected lncRNAs of the study subjects in 
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Additional file 8:  Comparison of the selected lncRNAs. Left: Comparison of 
the blood expressions of the 6 selected lncRNAs between adult and child-
hood controls. The adjusted P values are given for each comparison. Right: 
Principal component analysis bi-plot showing the scores of the samples 
(colored circles) and the loadings of the variables (i.e. the six selected 
lncRNA as grey arrows) along the first two principal components.
Additional file 9:  Comparison of the selected lncRNAs. Left: Comparison 
of the blood expression of the 6 selected lncRNAs between groups. The 
adjusted P-values are given for each comparison. Only those comparisons 
are depicted, where at least one significant difference was found. Right: 
Principal component analysis bi-plot showing the scores of the samples 
(colored circles) and the loadings of the variables (i.e. the six selected 
lncRNA as grey arrows) along the first two principal components.
Additional file 10: Comparison of the selected lncRNAs. Left: Comparison 
of the blood expression of the 6 selected lncRNAs between groups. The 
adjusted P-values are given for each comparison. Only those comparisons 
are depicted, where at least one significant difference was found. Right: 
Principal component analysis bi-plot showing the scores of the samples 
(colored circles) and the loadings of the variables (i.e. the six selected 
lncRNA as grey arrows) along the first two principal components.
Additional file 11: Comparison of the selected lncRNAs. Left: Comparison 
of the blood expression of the 6 selected lncRNAs between groups. The 
adjusted P-values are given for each comparison. Only those comparisons 
are depicted, where at least one significant difference was found. Right: 
Principal component analysis bi-plot showing the scores of the samples 
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lncRNA as grey arrows) along the first two principal components.
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lncRNA as grey arrows) along the first two principal components.
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are depicted, where at least one significant difference was found. Right: 
Principal component analysis bi-plot showing the scores of the samples 
(colored circles) and the loadings of the variables (i.e. the six selected 
lncRNA as grey arrows) along the first two principal components.
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of the blood expression of the 6 selected lncRNAs between groups. The 
adjusted P-values are given for each comparison. Only those comparisons 
are depicted, where at least one significant difference was found. Right: 
Principal component analysis bi-plot showing the scores of the samples 
(colored circles) and the loadings of the variables (i.e. the six selected 
lncRNA as grey arrows) along the first two principal components.
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